Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma
| Autor: | Florent Puisset, Martin Gauthier, Caroline Protin, Camille Laurent, Loic Ysebaert, Cécile Borel, Jean Marie Canonge, Sophie Perriat, Anaïs Grand, Lucie Oberic, Faustine Delzor |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Immunoconjugates Anaplastic large cell CD30 Ki-1 Antigen 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine In real life Medicine T-cell lymphoma Humans Pharmacology (medical) In patient Brentuximab vedotin Retrospective Studies Brentuximab Vedotin business.industry Lymphoma T-Cell Peripheral Combination chemotherapy medicine.disease 030220 oncology & carcinogenesis Neoplasm Recurrence Local business 030215 immunology medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(7) |
| ISSN: | 1477-092X |
| Popis: | Introduction Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies. We report here the outcomes of patients with various R/R Peripheral T Cell Lymphoma (PTCL) treated with Bv in real life practice. Method This was a retrospective, single-center study based on medical records of patients with R/R PTCL treated either with Bv alone or in combination with chemotherapy. Results Among 27 patients treated with Bv, neutropenia was the main serious adverse event observed in particular when Bv was used as combination treatment. The complete Response Rates (CRR) was 40.7%; it was significantly improved when Bv was used as combination treatment. The majority of eligible patients (7/10) underwent Stem Cell Transplantation. Median Progression Free Survival (PFS) and Overall Survival (OS) were 5.2 months and 12.5 months respectively. Conclusion Our current study shows that Bv used in combination with chemotherapy provides a high CRR and thereby allows SCT in R/R PTCL. The use of Bv treatments in this setting warrants further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|